1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024

EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024

  • June 2015
  • 37 pages
  • ID: 3085667
In this report:
The highest number of diagnosed prevalent cases of myasthenia gravis fell into the ≥## year age group in the ##MM, with ##,## cases (##.##% of all diagnosed prevalent cases of myasthenia gravis in the ##MM in 2024).
GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of myasthenia gravis in the ##MM, from ##,## cases in 2014 to ##,## cases in 2024, at an Annual Growth Rate (AGR) of ##.##% in the forecast period.

Summary

Table of Contents

Search Inside

EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024

Briefy

Myasthenia gravis is an autoimmune disease that affects the nerves and muscles and is characterized by muscle weakness and fatigue, especially weakness of the muscles controlling eye and eyelid movement, facial expression, chewing and talking. In some cases the muscles controlling breathing are also affected, which can lead to respiratory failure that requires intubation and mechanical ventilation, known as a myasthenic crisis. The muscle weakness seen in myasthenia gravis is most often caused by circulating antibodies that mistakenly attack healthy tissue and inhibit normal neuromuscular transmission by blocking or damaging muscle receptor cells.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of myasthenia gravis in the 7MM, from 106,845 cases in 2014 to 119,939 cases in 2024, at an Annual Growth Rate of ~1.2 percent in the forecast period. The more significant number of diagnosed prevalent cases of myasthenia gravis fell into the =75 year age group in the 7MM. The majority of diagnosed prevalent cases of myasthenia gravis in the 7MM in 2014 were women. The U.S. and the 5EU markets follow a similar pattern, in which Class III has the more important number of diagnosed prevalent cases. Japan (JP), however, has more cases in Class II than any other Class.

To build the epidemiological forecast of myasthenia gravis in the 7MM, GlobalData epidemiologists reviewed the literature and obtained country-specific, population-based studies that reported myasthenia gravis prevalence as determined via medical record reviews. GlobalData epidemiologists obtained country-specific diagnosed prevalence data for the U.S., Italy (IT), the United Kingdom (UK), and Japan (JP), thereby providing valuable analysis of epidemiological trends amongst the 7MM. This forecast also comprises age- and sex-specific segmentations, thereby providing exhaustive information about the characteristic of the disease in each market.

Overviewe

- The Myasthenia Gravis EpiCast Report offers an overview of the risk factors and overall trends of myasthenia gravis in the 7MM (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of myasthenia gravis, broken down by sex, age, and Myasthenia Gravis Foundation of America classifications (Class I, Class II, Class III, Class IV, and Class V).

- The myasthenia gravis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchasey

The Myasthenia Gravis EpiCast series will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall myasthenia gravis market.

- Quantify patient populations in the overall myasthenia gravis market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for myasthenia gravis therapeutics in each of the markets covered.

- Identify the percentage of myasthenia gravis prevalent cases by class.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Multiple Sclerosis  - Market Insight, Epidemiology and Market Forecast - 2027

Multiple Sclerosis  - Market Insight, Epidemiology and Market Forecast - 2027

  • $ 6250
  • Industry report
  • June 2018
  • by Delve Insight

DelveInsight’s ‘Multiple Sclerosis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well ...

Epilepsy  - Market Insight, Epidemiology and Market Forecast - 2027

Epilepsy  - Market Insight, Epidemiology and Market Forecast - 2027

  • $ 6250
  • Industry report
  • June 2018
  • by Delve Insight

DelveInsight’s ‘Epilepsy - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market ...

EPIOMIC EPIDEMIOLOGY SERIES: GAUCHER’S DISEASE FORECAST IN 30 MAJOR MARKETS 2018–2028

EPIOMIC EPIDEMIOLOGY SERIES: GAUCHER’S DISEASE FORECAST IN 30 MAJOR MARKETS 2018–2028

  • $ 5629
  • Industry report
  • July 2018
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Gaucher’s Disease in 30 Major MarketsGaucher’s Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on